Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline Cloos

Showing results (11-20 of 171) with videos related to

Pageof 18
Sort By:
Current Protocols in Cytometry|November 26, 2019
Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid LeukemiaWendelien Zeijlemaker, Angele Kelder, Jacqueline Cloos, et al.
Leukemia & Lymphoma|August 20, 2025
Flow cytometric and molecular MRD in AML: current methods, clinical applications and challengesLukas H Haaksma, Jacqueline Cloos, David C de Leeuw
Expert Review of Anticancer Therapy|March 13, 2013
Proteasome inhibitors in acute leukemiaDenise Niewerth, Ilse Dingjan, Jacqueline Cloos, et al.
Expert Review of Hematology|November 24, 2018
Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardizationGerrit J Schuurhuis, Gert J Ossenkoppele, Angèle Kelder, et al.
Best Practice & Research. Clinical Haematology|June 18, 2019
Can we incorporate MRD assessment into clinical practice in AML?Gert Ossenkoppele, Gerrit Jan Schuurhuis, Arjan van de Loosdrecht, et al.
Hemasphere|May 22, 2025
Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemiaTim R Mocking, Arjan A van de Loosdrecht, Jacqueline Cloos, et al.
Pathology|December 30, 2019
Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypesDiana Hanekamp, Costa Bachas, Arjan van de Loosdrecht, et al.
Anti-Cancer Agents in Medicinal Chemistry|February 10, 2009
Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs)Mahban Irandoust, Timo K van den Berg, Gertjan J L Kaspers, et al.
Expert Review of Hematology|September 23, 2014
Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment designRolf Wouters, David Cucchi, Gertjan J L Kaspers, et al.
BMC Bioinformatics|October 23, 2025
Computationally efficient multi-sample flow cytometry data analysis using Gaussian mixture modelsPhilip Rutten, Tim R Mocking, Jacqueline Cloos, et al.
Pageof 18

Showing results (11-20 of 171) with videos related to

Sort By:
Pageof 18
Current Protocols in Cytometry|November 26, 2019
Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid LeukemiaWendelien Zeijlemaker, Angele Kelder, Jacqueline Cloos, et al.
Leukemia & Lymphoma|August 20, 2025
Flow cytometric and molecular MRD in AML: current methods, clinical applications and challengesLukas H Haaksma, Jacqueline Cloos, David C de Leeuw
Expert Review of Anticancer Therapy|March 13, 2013
Proteasome inhibitors in acute leukemiaDenise Niewerth, Ilse Dingjan, Jacqueline Cloos, et al.
Expert Review of Hematology|November 24, 2018
Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardizationGerrit J Schuurhuis, Gert J Ossenkoppele, Angèle Kelder, et al.
Best Practice & Research. Clinical Haematology|June 18, 2019
Can we incorporate MRD assessment into clinical practice in AML?Gert Ossenkoppele, Gerrit Jan Schuurhuis, Arjan van de Loosdrecht, et al.
Hemasphere|May 22, 2025
Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemiaTim R Mocking, Arjan A van de Loosdrecht, Jacqueline Cloos, et al.
Pathology|December 30, 2019
Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypesDiana Hanekamp, Costa Bachas, Arjan van de Loosdrecht, et al.
Anti-Cancer Agents in Medicinal Chemistry|February 10, 2009
Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs)Mahban Irandoust, Timo K van den Berg, Gertjan J L Kaspers, et al.
Expert Review of Hematology|September 23, 2014
Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment designRolf Wouters, David Cucchi, Gertjan J L Kaspers, et al.
BMC Bioinformatics|October 23, 2025
Computationally efficient multi-sample flow cytometry data analysis using Gaussian mixture modelsPhilip Rutten, Tim R Mocking, Jacqueline Cloos, et al.
Pageof 18